Literature DB >> 7508268

(6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin.

D Willner1, P A Trail, S J Hofstead, H D King, S J Lasch, G R Braslawsky, R S Greenfield, T Kaneko, R A Firestone.   

Abstract

The (6-maleimidocaproyl)hydrazone of doxorubicin was synthesized and conjugated to several mAbs, including chimeric BR96, via a Michael addition reaction to thiol-containing mAbs. DTT reduction of disulfides present in the mAb was a reliable and general method for generating a consistent number of reactive SH groups. The conjugates, after purification by Bio-Beads, were free of unreacted linker and/or doxorubicin. All conjugates released doxorubicin under acidic conditions that mimic the lysosomal environment, while they were relatively stable at neutral pH. BR96 conjugates showed antigen-specific cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508268     DOI: 10.1021/bc00024a015

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  26 in total

1.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

2.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

Review 3.  Analytical methods for physicochemical characterization of antibody drug conjugates.

Authors:  Aditya Wakankar; Yan Chen; Yatin Gokarn; Fredric S Jacobson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 4.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

5.  Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy.

Authors:  Athulya Aravind; Yasuhiko Yoshida; Toru Maekawa; D Sakthi Kumar
Journal:  Drug Deliv Transl Res       Date:  2012-12       Impact factor: 4.617

6.  Novel Molecular Multilevel Targeted Antitumor Agents.

Authors:  Poonam Sonawane; Young A Choi; Hetal Pandya; Denise M Herpai; Izabela Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Cancer Transl Med       Date:  2017-06-08

Review 7.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

8.  Protein nanocapsules containing doxorubicin as a pH-responsive delivery system.

Authors:  Dongmei Ren; Felix Kratz; Szu-Wen Wang
Journal:  Small       Date:  2011-03-29       Impact factor: 13.281

9.  Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting.

Authors:  Vaikunth Cuchelkar; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-09-04       Impact factor: 4.939

10.  Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells.

Authors:  Xu Li; Cuixia Gao; Yupei Wu; C-Yan Cheng; Weiliang Xia; Zhiping Zhang
Journal:  J Mater Chem B       Date:  2015-01-02       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.